The FDA has started its two-day advisory committee meeting to determine if higher doses of opioids should be limited or removed from the market.
During the meeting, the FDA is soliciting feedback from clinical, patient, public health and research communities to better understand current clinical use of higher-dose opioids, situations that may warrant the use of higher doses and frequency of harm associated with higher doses.
Interested parties are asked to present data, information or views in writing or in person.
The FDA's Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesia Drug Products Advisory Committee is holding the meeting.